274 related articles for article (PubMed ID: 10820524)
61. More education is needed before we burden women with their HPV status.
Butterfield ED
BMJ; 2014 Feb; 348():g1443. PubMed ID: 24523378
[No Abstract] [Full Text] [Related]
62. Possible causes of low sensitivity of HPV-DNA testing for CIN2/3.
Guyot A; Fox J; Karim S; Kyi Ms
Acta Obstet Gynecol Scand; 2004 Feb; 83(2):217-8; author reply 219. PubMed ID: 14756746
[No Abstract] [Full Text] [Related]
63. Have we resolved how to triage equivocal cervical cytology?
Solomon D; Schiffman M
J Natl Cancer Inst; 2004 Feb; 96(4):250-1. PubMed ID: 14970266
[No Abstract] [Full Text] [Related]
64. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
Saleem A; Tristram A; Fiander A; Hibbitts S
Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
[TBL] [Abstract][Full Text] [Related]
65. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
Kaufman RH; Adam E
Gynecol Oncol; 1998 Sep; 70(3):317-8. PubMed ID: 9790780
[No Abstract] [Full Text] [Related]
66. [Cervical cancer screning: from cytology to HPV testing].
Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):289-292. PubMed ID: 31154708
[TBL] [Abstract][Full Text] [Related]
67. Hybrid capture based human papillomavirus typing in cervical screening compared to cytology and histology.
Birner P; Schindl M; Stani J; Oberhuber G; Czerwenka K; Vutuc C; Breitenecker G
Wien Klin Wochenschr; 2000 Sep; 112(17):761-6. PubMed ID: 11042905
[TBL] [Abstract][Full Text] [Related]
68. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
69. [Current methods of diagnosis of uterine cervix precancer and cancer (a literature review)].
Podistov IuI; Laktionov KP; Petrovichev NN
Klin Lab Diagn; 2003 Mar; (3):15-24. PubMed ID: 12715392
[No Abstract] [Full Text] [Related]
70. Usefulness of DNA ploidy measurement on liquid-based smears showing conflicting results between cytology and high-risk human papillomavirus typing.
Lorenzato M; Bory JP; Cucherousset J; Nou JM; Bouttens D; Thil C; Dez F; Evrard G; Quereux C; Birembaut P; Clavel C
Am J Clin Pathol; 2002 Nov; 118(5):708-13. PubMed ID: 12428790
[TBL] [Abstract][Full Text] [Related]
71. Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough?
Franco EL
J Natl Cancer Inst; 2010 Oct; 102(19):1451-3. PubMed ID: 20841606
[No Abstract] [Full Text] [Related]
72. Correspondence Re: M. Schiffman and A. Schatzkin, test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res. (suppl.), 54: 1944s-1947s, 1994.
Bosch FX; de Sanjosé S; Muñoz N
Cancer Res; 1994 Dec; 54(23):6288-9. PubMed ID: 7954479
[No Abstract] [Full Text] [Related]
73. Role of HPV testing in clinical practice.
Cuzick J
Virus Res; 2002 Nov; 89(2):263-9. PubMed ID: 12445665
[No Abstract] [Full Text] [Related]
74. Screening of cervical cancer: where do we go from here?
Kuo DY; Goldberg GL
Cancer Invest; 2003; 21(1):157-61. PubMed ID: 12643017
[No Abstract] [Full Text] [Related]
75. [Human papillomavirus].
Matsumoto K
Nihon Rinsho; 2010 Jun; 68 Suppl 6():345-9. PubMed ID: 20942076
[No Abstract] [Full Text] [Related]
76. [HPV test replaces Pap test in Uppsala].
Olovsson M; Aarnio R; Rezapour M; Segeblad B; Sjöö EL; Wilander E
Lakartidningen; 2013 Mar 26-Apr 9; 110(13-14):695-6. PubMed ID: 23634626
[No Abstract] [Full Text] [Related]
77. HR-HPV DNA to differentiate between cervical pemphigus and CIN: a case report.
Karanjgaokar V; Khan A; Ramachandra S; Pisal N
Arch Gynecol Obstet; 2008 Apr; 277(4):349-51. PubMed ID: 17906869
[No Abstract] [Full Text] [Related]
78. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
Fait G; Daniel Y; Kupferminc MJ; Lessing JB; Niv J; Bar-Am A
Gynecol Oncol; 1998 Sep; 70(3):319-22. PubMed ID: 9790781
[TBL] [Abstract][Full Text] [Related]
79. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
[TBL] [Abstract][Full Text] [Related]
80. The potential utility of HPV genotyping in screening and clinical management.
Castle PE
J Natl Compr Canc Netw; 2008 Jan; 6(1):83-95. PubMed ID: 18267061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
